The DOI matches its Crossref record, with a small difference in title or year.
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
Abstract
The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a multicenter, randomized, double-blind study, tested the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD) in 3,806 asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia). The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7.4 years. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol (LDL-C) reductions of 13.4% and 20.3%, respectively, which were 8.5% and 12.6% greater reductions than those obtained in the placebo group. The cholestyramine group experienced a 19% reduction in risk (p less than .05) of the primary end point--definite CHD death and/or definite nonfatal myocardial infarction--reflecting a 24% reduction in definite CHD death and a 19% reduction in nonfatal myocardial infarction. The cumulative seven-year incidence of the primary end point was 7% in the cholestyramine group v 8.6% in the placebo group. In addition, the incidence rates for new positive exercise tests, angina, and coronary bypass surgery were reduced by 25%, 20%, and 21%, respectively, in the cholestyramine group. The risk of death from all causes was only slightly and not significantly reduced in the cholestyramine group. The magnitude of this decrease (7%) was less than for CHD end points because of a greater number of violent and accidental deaths in the cholestyramine group. The LRC-CPPT findings show that reducing total cholesterol by lowering LDL-C levels can diminish the incidence of CHD morbidity and mortality in men at high risk for CHD because of raised LDL-C levels. This clinical trial provides strong evidence for a causal role for these lipids in the pathogenesis of CHD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In clinical studies, ezetimibe in monotherapy at 10 mg/day reduces LDL-C in hypercholesterolaemic patients by 15-22% with relatively high interindividual variation [261].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [261]
In the citing paper
“There are no clinically significant effects of age, sex, or race on ezetimibe pharmacokinetics, and no dosage adjustment is necessary in patients with mild hepatic impairment or mild-to-severe renal insufficiency.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [261]
In the citing paper
“Life-threatening liver failure with ezetimibe as monotherapy or in combination with statins is extremely rare.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [261]
In the citing paper
“The addition of ezetimibe to statin therapy does not appear to increase the incidence of elevated CK levels beyond what is noted with statin treatment alone [261].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [261]
In the citing paper
“Ezetimibe is rapidly absorbed and extensively metabolized to pharmacologically active ezetimibe glucuronide.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [261]
In the citing paper
“In clinical trials, bile acid sequestrants have contributed greatly to the demonstration of the efficacy of LDL-C lowering in reducing CV events in hypercholesterolaemic subjects, with a benefit proportional to the degree of LDL-C lowering.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [239]
In the citing paper
“In clinical trials, bile acid sequestrants have contributed greatly to the demonstration of the efficacy of LDL-C lowering in reducing CV events in hypercholesterolaemic subjects, with a benefit proportional to the degree of LDL-C lowering.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [239]
In the citing paper
“A meta-analysis of large-scale clinical trials involving combination therapy with ezetimibe and statins in patients with high-risk conditions such as FH, ACS, and PAD, confirmed the safety of combination therapy and cardiovascular event suppression resulting from its LDL-C-lowering effects667).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [667]
In the citing paper
“orally administered, colesevelam lowers HbA1c 0.5% in diabetes”
Citations
Cited by
Sorted by citations
Items 901–1,000 of 1,025
Azalanstat (RS-21607), a lanosterol 14α-demethylase inhibitor with cholesterol-lowering activity
Burton, P. M., Swinney, D. C., Heller, R. A., Dunlap, B., Chiou, M., Malonzo, E., Haller, J., Walker, K. A. M., Salari, A., Murakami, S., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00152-p · Cited by 31
Steinberg, D. H., Pittman, R. C., & Carew, T. E. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb11858.x · Cited by 31
Mendoza, S., Gámez, R., Noa, M., Más, R., Castaño, G., Mesa, R., Mesa, M., & de Armas, M. (2001) · Current Therapeutic Research · doi:10.1016/s0011-393x(01)80032-1 · Cited by 31
o, G. C., Fern??ndez, L., Más, R., Illnait, J., G??mez, R., Mendoza, S., Mesa, M., & Fern??ndez, J. (2005) · Drugs in R&D · doi:10.2165/00126839-200506040-00003 · Cited by 31
o, G. C., s, R. M., ndez, L. F., pez, E. L., rrez, J. A. G., Illnait, J., ndez, J. C. F., mez, R. G., & Alvarez, E. (2002) · Drugs in R&D · doi:10.2165/00126839-200203050-00008 · Cited by 31
Durrington, P. N. (1999) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.1999.0019 · Cited by 31
Currently available hypolipidaemic drugs and future therapeutic developments.
Farmer, J. A., & Gotto, A. (1995) · Baillière's Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(95)80177-4 · Cited by 35
Chemie und Biologie der Saragossasäuren/Squalestatine
Nadin, A. J., & Nicolaou, K. C. (1996) · Angewandte Chemie · doi:10.1002/ange.19961081505 · Cited by 31
Coronary Risk Factor Behavior Change in Hospital Personnel Following a Screening Program
Baier, C. A., Grodzin, C. J., Port, J. D., Leksas, L., & Tancredi, D. J. (1992) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(18)30845-6 · Cited by 31
Treatment of common lipoprotein disorders.
Brown, W., Goldberg, I. J., & Ginsberg, H. N. (1984) · Progress in cardiovascular diseases · doi:10.1016/0033-0620(84)90017-3 · Cited by 30
Farnier, M., Bruckert, É., Boileau, C., & Krempf, M. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.01.053 · Cited by 30
Milias, G. A., Panagiotakos, D. B., Pitsavos, C., Xenaki, D., Panagopoulos, G., & Stefanadis, C. (2006) · Lipids in Health and Disease · doi:10.1186/1476-511x-5-5 · Cited by 30
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 35
Zhou, E., Hoeke, G., Zhuang, L., Eibergen, A. C., Schonk, A. W., Koehorst, M., Boverhof, R., Havinga, R., Kuipers, F., Coşkun, T., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz253 · Cited by 30
Garg, S. K., Ritchie, P. J., Moser, E. G., Snell‐Bergeon, J. K., Freson, B. J., & Hazenfield, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01320.x · Cited by 30
Do Clinical Practice Guidelines Reflect Research Evidence?
Savoie, I., Kazanjian, A., & Bassett, K. L. (2000) · Journal of Health Services Research & Policy · doi:10.1177/135581960000500204 · Cited by 30
Randomised Controlled Trial of the Treatment of Hyperlipidaemia on Progression of Atherosclerosis
Lewis, B. (1985) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1985.tb08889.x · Cited by 30
Optimal management of hyperlipidemia in primary prevention of cardiovascular disease
Raza, J. A., Babb, J. D., & Movahed, A. (2004) · International Journal of Cardiology · doi:10.1016/j.ijcard.2003.07.039 · Cited by 30
Association Between Serum Apolipoprotein CII Concentration and Coronary Heart Disease
Gerber, Y., Goldbourt, U., Cohen, H., & Harats, D. (2002) · Preventive Medicine · doi:10.1006/pmed.2002.1045 · Cited by 30
Coronary artery bypass grafting in familial hypercholesterolemia
Kawasuji, M., Sakakibara, N., Takemura, H., Matsumoto, Y., Mabuchi, H., & Watanabe, Y. (1995) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(95)70398-5 · Cited by 30
Zema, M. J. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00585-9 · Cited by 30
Getting cardiologists interested in lipids
Roberts, W. C. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90898-m · Cited by 30
Corsini, A., Windier, E. T. E., & Farnier, M. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32831215db · Cited by 30
Hilleman, D. E., Monaghan, M. S., Ashby, C. L., Mashni, J. E., Woolley, K., & Amato, C. M. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.17.1415.34422 · Cited by 30
Singh, R. B., Niaz, M. A., Ghosh, S., Singh, R. B., & Rastogi, S. S. (1993) · Journal of the American College of Nutrition · doi:10.1080/07315724.1993.10718307 · Cited by 30
Glueck, C. J., Gordon, D. J., Nelson, J., Davis, C., & Tyroler, H. (1986) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/44.4.489 · Cited by 30
High-density lipoprotein cholesterol
Lavie, C. J., O’Keefe, J. H., Blonde, L., & Gau, G. T. (1990) · Postgraduate Medicine · doi:10.1080/00325481.1990.11704654 · Cited by 30
A commentary on the Rationale of the Diet-Heart Statement of the American Heart Association
Reiser, R. (1984) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/40.3.654 · Cited by 30
Decision Analytic Modeling: Some Uses in the Evaluation of New Pharmaceuticals
Glick, H. A., Kinosian, B. P., & Schulman, K. A. (1994) · Drug Information Journal · doi:10.1177/009286159402800306 · Cited by 30
Coarctation of the aorta: long-term follow-up and prediction of outcome after surgical correction.
Guntheroth, W. G. (1990) · Circulation · doi:10.1161/01.cir.81.4.1441 · Cited by 30
Jones, J. E., Tang, K. S., Barseghian, A., & Wong, N. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237432 · Cited by 34
Plana, N., Ibarretxe, D., Cabré, A., Ruiz, E., & Masana, L. (2014) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.04.002 · Cited by 29
Hsu, H., Lin, C., Lee, Y.-S., Wu, T., & Chien, K. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01567-1 · Cited by 30
Reducing global risk for cardiovascular disease: Using lifestyle changes and pharmacotherapy
Cheng, A., Braunstein, J. B., Himmelfarb, C. D., NASS, C. M., & Blumenthal, R. S. (2002) · Clinical Cardiology · doi:10.1002/clc.4950250503 · Cited by 30
Oxidised LDL, HDL cholesterol, LDL cholesterol levels in patients of coronary artery disease
Ghosh, J., Mishra, T. K., Rao, Y. N., & Aggarwal, S. K. (2006) · Indian Journal of Clinical Biochemistry · doi:10.1007/bf02913092 · Cited by 29
Luoma, P. V. (2007) · Annals of Medicine · doi:10.1080/07853890701379767 · Cited by 29
Castaño, G., Arruzazabala, M. L., Fernández, L., Más, R., Carbajal, D., Molina, V., Illnait, J., Mendoza, S., Gámez, R., Mesa, M., et al. (2006) · Current Therapeutic Research · doi:10.1016/j.curtheres.2006.06.004 · Cited by 29
Side‐chain oxysterol regulation of 3‐Hydroxy‐3‐methylglutaryl Coenzyme A reductase activity
Parish, E. J., Parish, S. C., & Li, S. (1995) · Lipids · doi:10.1007/bf02537828 · Cited by 29
Cholesterol and cardiovascular disease: no longer whether, but rather when, in whom, and how?
Levy, R. I. (1985) · Circulation · doi:10.1161/01.cir.72.4.686 · Cited by 29
Traditional Coronary Risk Factors in African Americans
Potts, J. L., & Thomas, J. W. (1999) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40502-6 · Cited by 29
Vedie, B., Jeunemaı̂tre, X., Mégnien, J. L., Myara, I., Trebeden‐Negre, H., Simon, A. C., & MOATTI, N. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.11.1780 · Cited by 29
Monitoring boundaries for adverse effects in long-term clinical trials
Lan, K. K. G., & Friedman, L. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90002-4 · Cited by 29
The Multifactor Primary Prevention Trial in G??teborg, Sweden
Wilhelmsen, L., Berglund, G., Elmfeldt, D., Samuelsson, O. G., & Svärdsudd, K. (1986) · Drugs · doi:10.2165/00003495-198600311-00009 · Cited by 29
HDL Heterogeneity and Atherosclerosis
Tailleux, A., Fruchart, J., & Parkes, J. G. (1996) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408369609083060 · Cited by 29
Chapter 16. Treatment of Hypercholesterolemia
Roth, B. D., Sliskovic, D. R., & Trivedi, B. K. (1989) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60538-2 · Cited by 29
Sudden death and the decline in coronary heart disease mortality
Kuller, L. H., Perper, J. A., Dai, W. S., Rutan, G. H., & Traven, N. D. (1986) · Journal of Chronic Diseases · doi:10.1016/0021-9681(86)90136-0 · Cited by 29
Brett, A. S. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90218-m · Cited by 29
In vivo transfer of cholesterol from plasma into human aortic tissue
Stender, S., & Hjelms, E. (1987) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365518709168151 · Cited by 29
Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin
Chao, Y. S., Chen, J. S., Hunt, V. M., Kuron, G. W., Karkas, J. D., Liou, R., & Alberts, A. W. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf01409400 · Cited by 29
Current strategies in the diagnosis and management of lower extremity peripheral vascular disease
Wilt, T. J. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599110 · Cited by 29
Insulin Resistance and Cardiovascular Drugs
Lithell, H. (1992) · Clinical and Experimental Hypertension · doi:10.3109/10641969209036178 · Cited by 29
The lipid hypothesis and the role of hemodynamics in atherogenesis
Stehbens, W. E. (1990) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(05)80034-9 · Cited by 29
Dietary treatment for familial hypercholesterolaemia
Poustie, V., & Rutherford, T. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001918 · Cited by 29
Friedman, H. S., Rajagopalan, S., Barnes, J. P., & Roseman, H. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.02.011 · Cited by 29
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
Turner, T. A., & Stein, E. A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.004 · Cited by 28
Dyslipidemias in Patients With Diabetes Mellitus: Classification and Risks and Benefits of Therapy
Oki, J. C. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb04369.x · Cited by 28
Knutsen, S. F., & Knutsen, R. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700116 · Cited by 28
Low‐Density Lipoprotein Apheresis: Clinical Results with Different Methods
Bambauer, R. (2002) · Artificial Organs · doi:10.1046/j.1525-1594.2002.06837.x · Cited by 28
Colesevelam: Potential Uses for the Newest Bile Resin
Steinmetz, K. L., & Schonder, K. S. (2005) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2005.tb00154.x · Cited by 28
Silverstein, F. E. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018895417831 · Cited by 28
Low‐Density Lipoprotein Apheresis for Prevention and Regression of Atherosclerosis: Clinical Results
Bambauer, R., Olbricht, C. J., & Schoeppe, E. (1997) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.1997.tb00145.x · Cited by 27
Jp, S., Haapanen, A., Harju, E., Jokela, H., & Riekkinen, H. (1989) · European Journal of Vascular Surgery · doi:10.1016/s0950-821x(89)80094-5 · Cited by 28
Jacobson, T. A., & Amorosa, L. (1994) · American Journal of Cardiology · doi:10.1016/0002-9149(94)90629-7 · Cited by 29
Elton, P., Ryman, A., Hammer, M., & Page, F. (1994) · Journal of Epidemiology & Community Health · doi:10.1136/jech.48.1.22 · Cited by 28
Successful program for recovery of dropouts to a clinical trial
Probstfield, J. L., Russell, M. L., Henske, J. C., Reardon, R., & Insull, W. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90615-7 · Cited by 28
Inherited Disorders of Lipid Transport
Schonfeld, G. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30323-2 · Cited by 29
Lipids, Apolipoproteins and Lipoproteins
Rader, D. J., & Brewer, H. B. (1994) · Developments in cardiovascular medicine · doi:10.1007/978-94-011-1130-0_6 · Cited by 27
Obesity and nutrition in elderly diabetic patients
Kannel, W. B., Garrison, R. J., & Wilson, P. W. F. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90534-6 · Cited by 28
Role of nutrition in the prevention and treatment of coronary heart disease in women
Kris-Etherton, P. M., & Krummel, D. A. (1993) · Journal of the American Dietetic Association · doi:10.1016/0002-8223(93)92035-v · Cited by 27
Effects of dietary fatty acids in an animal model of focal glomerulosclerosis
Wheeler, D. C., Nair, D. R., Persaud, J. W., Jeremy, J. Y., Chappell, M. E., Varghese, Z., & Moorhead, J. F. (1991) · Kidney International · doi:10.1038/ki.1991.116 · Cited by 28
Biological and Medical Aspects of Active Heal Transport of Bile Acids
Hofmann, A. F., Schteingart, C. D., & Lillienau, J. (1991) · Annals of Medicine · doi:10.3109/07853899109148043 · Cited by 28
The effects of lowering serum cholesterol on coronary heart disease risk
Rossouw, J. E. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30182-1 · Cited by 28
Statins prevent coronary heart disease.
Oliver, M. F. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92399-3 · Cited by 29
Role of colesevelam in combination lipid-lowering therapy
Jones, M. R., & Nwose, O. M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0037-0 · Cited by 27
Sivashanmugarajah, A. S., Fulcher, J., SULLIVAN, D. R., Elam, M. B., Jenkins, A. J., & KEECH, A. C. (2019) · Internal Medicine Journal · doi:10.1111/imj.14429 · Cited by 26
The Role of Statins in Current Guidelines
Rached, F. H., & Santos, R. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00861-9 · Cited by 30
Nakamura, M., Iso, H., Kitamura, A., Imano, H., Kiyama, M., Yokoyama, S., Kayamori, Y., Koyama, I., Nishimura, K., Nakai, M., et al. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.03.026 · Cited by 27
Harchaoui, K. E., Akdim, F., Stroes, E. S. G., Trip, M. D., & Kastelein, J. J. P. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808040-00003 · Cited by 27
Grapefruit pectin inhibits hypercholesterolemia and atherosclerosis in miniature swine
Baekey, P., Cerda, J. J., Burgin, C. W., Robbins, F. L., Rice, R. W., & Baumgartner, T. G. (1988) · Clinical Cardiology · doi:10.1002/clc.4960110903 · Cited by 27
Major Differences in Cardiovascular Risk Indicators by Educational Status
Gran, B. (1995) · Scandinavian Journal of Social Medicine · doi:10.1177/140349489502300103 · Cited by 27
American College of Endocrinology Pre-Diabetes Consensus Conference: Part Two
Bloomgarden, Z. T. (2008) · Diabetes Care · doi:10.2337/dc08-zb11 · Cited by 26
Combined effect ofLactobacillus acidophilusandβ-cyclodextrin on serum cholesterol in pigs
Alonso, L., Fontecha, J., & Cuesta, P. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515003736 · Cited by 27
Mavrikakis, M., Sfikakis, P. P., Kontoyannis, S. A., Antoniades, L., Kontoyannis, D. A., & Moulopoulou, D. (1991) · Calcified Tissue International · doi:10.1007/bf02556220 · Cited by 27
Digital flashing tomosynthesis: a promising technique for angiocardiographic screening
Stiel, G. M., Stiel, L. S. G., Klotz, E., & Nienaber, C. A. (1993) · IEEE Transactions on Medical Imaging · doi:10.1109/42.232261 · Cited by 28
Effects of an ultra-long-distance (1000 km) race on lipid metabolism
Nagel, D. W., Seiler, D., Franz, H., Leitzmann, C., & Jung, K. (1989) · European Journal of Applied Physiology · doi:10.1007/bf02396574 · Cited by 27
Lipid-lowering therapy after an atherosclerotic event
Roberts, W. C. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90511-0 · Cited by 27
Molecular cloning and expression of rabbit pancreatic cholesterol esterase
Colwell, N. S., Aleman-Gomez, J. A., & Kumar, B. V. (1993) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(93)90288-o · Cited by 27
Contraception and dyslipidemia
Knopp, R. H., LaRosa, J. C., & Burkman, R. T. (1993) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(12)90941-2 · Cited by 27
Theriault, R. L., & Sellin, R. V. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057847 · Cited by 27
Siscovick, D. S., Ekelund, L. G., Hyde, J. S., Johnson, J. L., Gordon, D. J., & LaRosa, J. C. (1988) · American Journal of Public Health · doi:10.2105/ajph.78.11.1428 · Cited by 27
The European Study Group∗ (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90762-n · Cited by 27
Hypercholesterolemia and inflammation—Cooperative cardiovascular risk factors
Gallo, A., Goff, W. L., Santos, R. D., Fichtner, I., Carugo, S., Corsini, A., Sirtori, C. R., & Ruscica, M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14326 · Cited by 29
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Blom, D. J., Dent, R. E., Castro, R. D. C., & Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s102564 · Cited by 27
Alder, M., Bavishi, A. A., Zumpf, K. B., Peterson, J., & Stone, N. J. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.03.056 · Cited by 26
Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST)
Pressman, A. R., Avins, A. L., Neuhaus, J. M., Ackerson, L., & Rudd, P. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.12.003 · Cited by 26
Optimal lipid modification: the rationale for combination therapy
Backes, J. M., Gibson, C., & Howard, P. A. (2005) · Vascular Health and Risk Management · doi:10.2147/vhrm.2005.1.4.317 · Cited by 26
New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk
Adhyaru, B. B., & Jacobson, T. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.002 · Cited by 27
Gulizia, M. M., Colivicchi, F., Ricciardi, G., Giampaoli, S., Maggioni, A. P., Averna, M. R., Graziani, M. S., Ceriotti, F., Mugelli, A., Rossi, F., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux029 · Cited by 27
Park, M. Y., Kim, J., Kim, S. H., & Whang, K. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4125 · Cited by 26
Optimization of β-Quantification Methods for High-Throughput Applications
Cole, T. G., Ferguson, C. A., Gibson, D. W., & Nowatzke, W. L. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.712 · Cited by 26
Metadata
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1984-01-20
- Volume
- 251
- Issue
- 3
- Pages
- 351
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4248021162
- Cited by
- 2,747
- References
- 0
- Citations by year
- 2026: 18 · 2025: 14 · 2024: 27 · 2023: 19 · 2022: 20 · 2021: 26 · 2020: 17 · 2019: 34 · 2018: 31 · 2017: 33 · 2016: 42 · 2015: 58 · 2014: 51 · 2013: 46 · 2012: 45
- FWCI
- 196.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- cholestyramine, bile acid sequestrants, primary hypercholesterolemia, type II hyperlipoproteinemia, coronary artery disease, LDL cholesterol, total cholesterol, myocardial infarction, coronary heart disease mortality, cholesterol-lowering diet, cardiovascular risk reduction
- MeSH terms
- Adult, Cholesterol, Cholestyramine Resin, Clinical Trials as Topic, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Lipoproteins, Male, Middle Aged, Mortality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
